Want to see TSE:MPH full AI Analyst Report?
MPH Stock Chart & Stats
C$1.25
C$0.01(1.22%)
At close: 4:00 PM EST
C$1.25
C$0.01(1.22%)
Day’s Range― - ―
52-Week RangeC$0.85 - C$1.43
Previous CloseN/A
Volume1.00K
Average Volume (3M)1.72K
Market Cap
C$13.46M
Enterprise ValueC$9.70M
Total Cash (Recent Filing)C$1.54M
Total Debt (Recent Filing)C$803.00K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding10,436,313
10 Day Avg. Volume717
30 Day Avg. Volume1,717
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.92
Price to Sales (P/S)0.41
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Capital StructureMedicure’s very low debt burden and minimal total debt materially reduce near-term default and interest-service risk. This conservative capital structure preserves strategic optionality and gives management time to execute commercialization or fundraising plans without immediate refinancing pressure.
Sustained Top-line MomentumConsistent TTM revenue growth indicates product demand and commercial traction in the cardiovascular niche. Durable topline momentum supports scale benefits for distribution and may enable investment in marketing or development that compounds revenue growth over multiple quarters if margins stabilize.
Specialty Cardiovascular Commercialization ModelA focused specialty pharma model with commercialization expertise and territorial marketing rights yields repeatable product revenues and partner-based deal structures. This niche positioning supports defensibility versus broad generics and enables targeted resource allocation across development and sales.
Bears Say
Sharp Gross Margin CompressionRapid, sustained margin erosion signals worsening product economics or higher COGS and weakens the firm's ability to convert sales into profit. If structural, lower margins reduce reinvestment capacity, shrink buffers for commercial expansion, and make profitability reliant on cost cuts or pricing power that may be limited.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow erodes liquidity and forces reliance on cash reserves or external financing. Over months, this constrains investment in launches or trials, raises dilution or debt risk, and limits the company's ability to respond to competitive or regulatory demands without raising capital.
Eroding Equity And Sustained LossesA shrinking equity base and repeated net losses indicate shareholder value erosion and a weakening capital cushion. Continued losses at this scale increase pressure for dilutive financing or strategic exits, and reduce the firm’s ability to absorb setbacks in product launches or reimbursement changes over the medium term.
Medicure News
MPH FAQ
What was Medicure Inc’s price range in the past 12 months?
Medicure Inc lowest stock price was C$0.85 and its highest was C$1.43 in the past 12 months.
What is Medicure Inc’s market cap?
Medicure Inc’s market cap is C$13.46M.
When is Medicure Inc’s upcoming earnings report date?
Medicure Inc’s upcoming earnings report date is Aug 26, 2026 which is in 55 days.
How were Medicure Inc’s earnings last quarter?
Currently, no data Available
Is Medicure Inc overvalued?
According to Wall Street analysts Medicure Inc’s price is currently Overvalued.
Does Medicure Inc pay dividends?
Medicure Inc does not currently pay dividends.
What is Medicure Inc’s EPS estimate?
Medicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicure Inc have?
Medicure Inc has 10,436,313 shares outstanding.
What happened to Medicure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medicure Inc?
Currently, no hedge funds are holding shares in TSE:MPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicure Inc
Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.
Technical Analysis
Aequus Pharmaceuticals
―
Pharmadrug
―
Mountain Valley MD
―
Medexus Pharmaceuticals Inc
―
Xebra Brands Ltd.
―
Options Prices
Currently, No data available
---